| scholarly article | Q13442814 |
| P2093 | author name string | P M George | |
| M E Hodson | |||
| P Cullinan | |||
| D Bilton | |||
| N J Simmonds | |||
| W Banya | |||
| N Pareek | |||
| P2860 | cites work | Dornase alfa for cystic fibrosis | Q24236803 |
| Nebulised hypertonic saline for cystic fibrosis | Q24241042 | ||
| Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease | Q29618681 | ||
| Timing of referral for lung transplantation for cystic fibrosis: overemphasis on FEV1 may adversely affect overall survival | Q33543150 | ||
| Clinical outcome in relation to care in centres specialising in cystic fibrosis: cross sectional study | Q33801253 | ||
| Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group | Q34290556 | ||
| Gender gap in cystic fibrosis mortality | Q34425312 | ||
| Relationship between nutritional status and lung function in cystic fibrosis: cross sectional and longitudinal analyses from the German CF quality assurance (CFQA) project | Q35535262 | ||
| Cystic fibrosis: current survival and population estimates to the year 2000. | Q36253480 | ||
| Medium term treatment of stable stage cystic fibrosis with recombinant human DNase I. | Q36548175 | ||
| Survival effect of lung transplantation among patients with cystic fibrosis | Q36848757 | ||
| Determinants of mortality from cystic fibrosis in Canada, 1970-1989. | Q43698922 | ||
| Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial | Q44602962 | ||
| A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis | Q46900190 | ||
| A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities | Q46922742 | ||
| Diabetes is associated with dramatically decreased survival in female but not male subjects with cystic fibrosis | Q47739161 | ||
| Risk of death in cystic fibrosis patients with severely compromised lung function. | Q50887135 | ||
| An international/multicentre report on patients with cystic fibrosis (CF) over the age of 40 years. | Q51120992 | ||
| Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. | Q51711090 | ||
| Noninvasive ventilation in cystic fibrosis patients with acute or chronic respiratory failure. | Q51726178 | ||
| International guidelines for the selection of lung transplant candidates: 2006 update--a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. | Q53253288 | ||
| Efficacy of aerosolized tobramycin in patients with cystic fibrosis. | Q54237890 | ||
| Effect of Treatment with Dornase Alpha on Airway Inflammation in Patients with Cystic Fibrosis | Q61791581 | ||
| Prediction of Mortality in Patients with Cystic Fibrosis | Q67469870 | ||
| Diabetes mellitus associated with cystic fibrosis | Q68276767 | ||
| Comparison of effectiveness of pancreatic enzyme preparations in cystic fibrosis | Q70533113 | ||
| Standardised lung function testing | Q70587808 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cystic fibrosis | Q178194 |
| P304 | page(s) | d1008 | |
| P577 | publication date | 2011-02-28 | |
| P1433 | published in | The BMJ | Q546003 |
| P1476 | title | Improved survival at low lung function in cystic fibrosis: cohort study from 1990 to 2007. | |
| P478 | volume | 342 |
| Q58572838 | Allergic Bronchopulmonary Aspergillosis-A Luminal Hypereosinophilic Disease With Extracellular Trap Cell Death |
| Q47103711 | Antibiotic perturbation of mixed-strain Pseudomonas aeruginosa infection in patients with cystic fibrosis |
| Q35178544 | Association between socioeconomic status, sex, and age at death from cystic fibrosis in England and Wales (1959 to 2008): cross sectional study |
| Q64111377 | Cardiopulmonary Exercise Testing: Another Tool in the Prognostication Tool Kit for Cystic Fibrosis |
| Q38124849 | Cell therapy for cystic fibrosis |
| Q53171875 | Chest computed tomography scores are predictive of survival in patients with cystic fibrosis awaiting lung transplantation. |
| Q39740014 | Consequences of Expiratory Flow Limitation at Rest in Subjects with Cystic Fibrosis. |
| Q51424428 | Cystic Fibrosis: The Dawn of a New Therapeutic Era. |
| Q89219005 | Cystic fibrosis |
| Q36254493 | Cystic fibrosis physicians' perspectives on the timing of referral for lung transplant evaluation: a survey of physicians in the United States. |
| Q38809559 | Does current reporting of lung function by the UK cystic fibrosis registry allow a fair comparison of adult centres? |
| Q60922612 | Dynamic Prediction of Survival in Cystic Fibrosis: A Landmarking Analysis Using UK Patient Registry Data |
| Q42728646 | Effect of dornase alfa on inflammation and lung function: potential role in the early treatment of cystic fibrosis |
| Q38813293 | Eosinophilic Otitis Media: the Aftermath of Eosinophil Extracellular Trap Cell Death. |
| Q51181329 | Estimating peak oxygen uptake in adolescents with cystic fibrosis. |
| Q37631978 | Global impact of bronchiectasis and cystic fibrosis |
| Q40361294 | Heterogeneity in Survival in Adult Patients With Cystic Fibrosis With FEV1 < 30% of Predicted in the United States |
| Q57651819 | ICU outcomes in cystic fibrosis following invasive ventilation |
| Q39434813 | Immunomodulatory Cell Therapy to Target Cystic Fibrosis Inflammation |
| Q37979246 | Inhaled mannitol for the treatment of cystic fibrosis |
| Q40973759 | Lung function comparison between two decades in cystic fibrosis children: A single centre study |
| Q92705518 | Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines |
| Q39008114 | Lung transplantation for cystic fibrosis: an update |
| Q38178773 | Management of comorbidities in older patients with cystic fibrosis. |
| Q38113749 | Managing the underlying cause of cystic fibrosis: a future role for potentiators and correctors |
| Q38139191 | Nontuberculous mycobacteria: the changing epidemiology and treatment challenges in cystic fibrosis. |
| Q26825799 | Pathophysiology of cystic fibrosis and drugs used in associated digestive tract diseases |
| Q47381971 | Physiological markers of exercise capacity and lung disease severity in cystic fibrosis |
| Q54652020 | Prognostication in cystic fibrosis: another futile pastime? |
| Q38248996 | Putting lung function and physiology into perspective: cystic fibrosis in adults |
| Q59510282 | Referral to lung transplantation- too little, too late |
| Q38910874 | Survival Comparison of Patients With Cystic Fibrosis in Canada and the United States: A Population-Based Cohort Study |
| Q90387464 | The future of cystic fibrosis care: a global perspective |
| Q28388812 | Understanding the natural progression in %FEV1 decline in patients with cystic fibrosis: a longitudinal study |
| Q36300937 | Within-host whole genome analysis of an antibiotic resistant Pseudomonas aeruginosa strain sub-type in cystic fibrosis |
| Q89353222 | [Epidemiological trends of cystic fibrosis in France: 10-year perspective] |
Search more.